LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clostridium difficile Examined by Different Methods

By LabMedica International staff writers
Posted on 30 Apr 2018
Image: A positive C. DIFF QUIK CHEK COMPLETE. The assay simultaneously tests for GDH and Toxins A & B providing actionable C. difficile results in less than 30 minutes (Photo courtesy of Alere).
Image: A positive C. DIFF QUIK CHEK COMPLETE. The assay simultaneously tests for GDH and Toxins A & B providing actionable C. difficile results in less than 30 minutes (Photo courtesy of Alere).
The epidemiology of Clostridium difficile infection (CDI) has shifted in the last decade and is now affecting populations previously at low risk to include healthy adults, peripartum women and young children.

The point prevalence of Clostridium difficile stool shedding in hospitalized infants from two neonatal intensive care units (NICUs) was examined utilizing standard clinical testing compared with duplex polymerase chain reaction (PCR) to identify toxigenic and non-toxigenic C. difficile strains.

Pediatric disease specialists at University of Nebraska Medical Center (Omaha, NE, USA) included all infants from the two NICUs affiliated with a single academic medical center were eligible for inclusion in the point prevalence survey. Stool collection was blinded to patient characteristics and occurred during a one-week period at each NICU and repeated with a second weeklong collection six months later to increase sample size.

Stools were tested for C. difficile using enzyme immunoassay (EIA) with samples testing +/+ or +/− subsequently evaluated by Loop-Mediated Isothermal Amplification. Cytotoxicity assays were performed on all samples positive for C. difficile by any modality (Clostridium difficile Toxin/Antitoxin kit. A rapid thermocycler was used to specifically amplify a conserved region of both toxigenic and non-toxigenic C. difficile tpi gene and a non-repeat region of the toxigenic C. difficile tcdB gene.

The scientists collected 84 stools from unique infants for evaluation. EIA results showed six+/+ (7.1%), seven +/− (8.3%), and 71 −/− [84.5%] samples. All six EIA +/+ were confirmed as toxigenic C. difficile by LAMP; 6/7 EIA +/− were negative by LAMP with one identified as invalid. Duplex PCR concurred with LAMP in all six stools positive for toxigenic C. difficile. PCR identified two EIA −/− stools positive for tpi, indicating shedding of non-toxigenic C. difficile. Cytotoxicity assay was positive in 4/6 duplex PCR positive samples and negative for all stools that were EIA +/− but negative by molecular testing.

The authors concluded that C. difficile blinded point prevalence in infants from two NICUs was 7.1% by molecular methods; and lower than expected based on historical incidence estimates. In house duplex PCR had excellent concordance with clinically available LAMP and EIA tests, and added detection of non-toxigenic C. difficile strain shedding. Evolving NICU care practices may be influencing the composition of infant gut microbiota and reducing the point prevalence of C. difficile shedding in NICU patient stools. The study was published on April 13, 2018, in the journal BMC Pediatrics.

Related Links:
University of Nebraska Medical Center

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more